Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.

Goutelle S, Baudry T, Gagnieu MC, Boibieux A, Livrozet JM, Peyramond D, Chidiac C, Tod M, Ferry T; Lyon HIV Cohort Study Group.

Antimicrob Agents Chemother. 2013 Jan;57(1):517-23. doi: 10.1128/AAC.01822-12. Epub 2012 Nov 12.

2.

Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.

Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, Lazzarin A, Castagna A.

New Microbiol. 2005 Apr;28(2):119-25.

PMID:
16035256
3.

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.

Antivir Ther. 2007;12(5):825-30.

PMID:
17713166
4.

Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.

Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E.

Ther Drug Monit. 2010 Dec;32(6):782-6. doi: 10.1097/FTD.0b013e3181fa53b7.

PMID:
20926993
5.

Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.

Seminari E, Guffanti M, Villani P, Gianotti N, Cusato M, Fusetti G, Galli A, Castagna A, Regazzi M, Lazzarin A.

Eur J Clin Pharmacol. 2005 Aug;61(7):545-9. Epub 2005 Jul 23.

PMID:
16041598
6.

Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.

HIV Med. 2010 May;11(5):326-33. doi: 10.1111/j.1468-1293.2009.00785.x. Epub 2010 Dec 9.

7.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.

Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. Epub 2006 Aug 28.

8.

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.

Di Biagio A, Rosso R, Loregian A, Pagni S, Sormani MP, Cenderello G, Palù G, Viscoli C.

J Infect Chemother. 2012 Aug;18(4):587-90. doi: 10.1007/s10156-012-0402-y. Epub 2012 Mar 16.

PMID:
22422300
9.

Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.

Dailly E, Tribut O, Tattevin P, Arvieux C, Perré P, Raffi F, Jolliet P.

Eur J Clin Pharmacol. 2006 Jul;62(7):523-6. Epub 2006 Jun 9.

PMID:
16763827
10.

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.

von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.

J Antimicrob Chemother. 2008 Sep;62(3):579-82. doi: 10.1093/jac/dkn204. Epub 2008 May 13.

PMID:
18477709
11.

Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.

Bonora S, Calcagno A, Vigano O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G, Rusconi S.

Curr HIV Res. 2014;12(5):339-46.

PMID:
25106410
12.

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.

Eur J Clin Pharmacol. 2007 Oct;63(10):935-40. Epub 2007 Jul 31.

PMID:
17665183
13.

Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.

Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM; NEAT Unboosted Atazanavir Cohort Study Group.

J Antimicrob Chemother. 2011 Oct;66(10):2372-8. doi: 10.1093/jac/dkr316. Epub 2011 Aug 5.

14.

Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.

Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Fucile S, Clementi E.

Fundam Clin Pharmacol. 2013 Apr;27(2):216-22. doi: 10.1111/j.1472-8206.2011.01005.x. Epub 2011 Nov 2.

PMID:
22044510
15.

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

Ther Drug Monit. 2007 Oct;29(5):648-51.

PMID:
17898658
16.

Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.

Regazzi M, Villani P, Gulminetti R, Cusato M, Brandolini M, Tinelli C, Barassi A, Maserati R, Sighinolfi L, D'Arminio Monforte A, Melzi D'Eril GV.

Ther Drug Monit. 2011 Jun;33(3):303-8. doi: 10.1097/FTD.0b013e31821c2772.

17.

Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients.

Avihingsanon A, Kerr SJ, Punyawudho B, van der Lugt J, Gorowara M, Ananworanich J, Lange JM, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K.

AIDS Res Hum Retroviruses. 2013 Dec;29(12):1541-6. doi: 10.1089/aid.2013.0069. Epub 2013 Oct 2.

18.

Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.

Barrail-Tran A, Mentré F, Cosson C, Piketty C, Chazallon C, Gérard L, Girard PM, Taburet AM.

Antimicrob Agents Chemother. 2010 Feb;54(2):614-9. doi: 10.1128/AAC.00797-09. Epub 2009 Dec 7.

19.

Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.

Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni M, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G.

Antivir Ther. 2011;16(4):499-504. doi: 10.3851/IMP1802.

PMID:
21685537
20.

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

Song I, Borland J, Chen S, Lou Y, Peppercorn A, Wajima T, Min S, Piscitelli SC.

Br J Clin Pharmacol. 2011 Jul;72(1):103-8. doi: 10.1111/j.1365-2125.2011.03947.x.

Supplemental Content

Support Center